LifeTech Scientific Corporation

Equities

1302

KYG548721177

Advanced Medical Equipment & Technology

Market Closed - Hong Kong S.E. Other stock markets 09:08:05 31/05/2024 BST			5-day change	1st Jan Change
1.69 ^HKD	+0.60%		-2.31%	-28.09%

05-16	LifeTech Scientific Completes Follow-up of Phase 2 Clinical Study of IBS Coronary Scaffold	MT
05-15	LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System	CI

Lifetech Scientific Corporation Announces Resignation of as Fu Feng as Non-Executive Director

April 19, 2021 at 10:21 am

LifeTech Scientific Corporation announced that the Board received the letter of resignation from Mr. FU Feng ("Mr. FU") whereby Mr. FU tendered his resignation as non-executive Director of the Company with effect from 19 April 2021, as China Everbright Limited is no longer a substantial shareholder of the Company.

Latest news about LifeTech Scientific Corporation

LifeTech Scientific Completes Follow-up of Phase 2 Clinical Study of IBS Coronary Scaffold	05-16	MT
LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System	05-15	CI
Lifetech Scientific Buys Shares For Employee Incentive Scheme	04-11	MT
Lifetech Scientific Unit Invests 340 Million Yuan in Structured Deposits	04-04	MT
Lifetech Scientific Books Lower 2023 Profit Despite Surge in Revenue	03-28	MT
LifeTech Scientific Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
LifeTech Scientific Flags Significant Profit Drop in 2023	03-08	MT
Lifetech Scientific Corporation Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023	03-08	CI
LifeTech Scientific to Grant 174.8 Million Share Options	01-25	MT
LifeTech Scientific Gets Regulatory Nod to Register Peripheral Thrombus Aspiration Catheter	11-09	MT
LifeTech Scientific's H1 Attributable Profit Grows on Higher Revenue	30/08/23	MT
LifeTech Scientific Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
China Grants Official Registration Approval for LifeTech Scientific's Surgical Navigation System	21/08/23	MT
Epione Surgical Navigation System Obtained Official Registration Approval by the China NMPA	20/08/23	CI
Jenscare Scientific, LifeTech Complete Treatment for Valve Replacement Product; Jenscare Shares Rise 3%	07/08/23	MT
LifeTech Scientific Unit Invests 50 Million Yuan in Structured Deposit Product by Bank of Ningbo	12/07/23	MT
LifeTech Scientific Completes Patient Enrollment for Phase 3 Study of Coronary Scaffold System	10/07/23	MT
Lifetech Scientific Corporation Announces Enrollment in the Phase Iii Clinical Study of IbsÂ®? Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed	10/07/23	CI
LifeTech Scientific Corporation Announces Publication of the Three-Year Follow-Up Results of FIM Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System	12/04/23	CI
LifeTech Scientific Logs 68.6% Drop in 2022 Profit	29/03/23	MT
LifeTech Scientific Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Lifetech Scientific and Jenscare Scientific to Cooperate on Business Development	08/02/23	MT
LifeTech Scientific Corporation Enters Strategic Cooperation Agreement with Jenscare Scientific Co., Ltd	06/02/23	CI
Lifetech Scientific Completes Patient Enrollment for China Phase II Clinical Trial of Coronary Scaffold System	13/12/22	MT
LifeTech Scientific Corporation Announces Enrollment in the China Randomized Controlled Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed	13/12/22	CI

Chart LifeTech Scientific Corporation

Duration

Period

More charts

Company Profile

LifeTech Scientific Corporation is an investment holding company principally engaged in the manufacturing and marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The Company operates through three business segments. The Congenital Heart Diseases Business segment is engaged in the research and development, manufacture and trading of devices related to congenital and structural heart diseases. The Peripheral Vascular Diseases Business segment is engaged in the research and development, manufacture and trading of devices related to peripheral vascular diseases. The Surgical Vascular Repair Business segment is engaged in the research and development, manufacture and trading of devices related to surgical vascular repair.

Sector

Advanced Medical Equipment & Technology

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for LifeTech Scientific Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.565 CNY

Average target price

2.436 CNY

Spread / Average Target

+55.65%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
LIFETECH SCIENTIFIC CORPORATION	-28.09%	1B
THERMO FISHER SCIENTIFIC	+7.01%	217B
DANAHER CORPORATION	+11.01%	190B
INTUITIVE SURGICAL, INC.	+19.20%	143B
BOSTON SCIENTIFIC CORPORATION	+30.79%	111B
SIEMENS HEALTHINEERS AG	+1.48%	64.59B
EDWARDS LIFESCIENCES CORPORATION	+13.95%	52.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.16%	48.45B
AGILENT TECHNOLOGIES, INC.	-6.20%	38.03B
GE HEALTHCARE TECHNOLOGIES INC.	+0.91%	35.61B

Other Advanced Medical Equipment & Technology